Epithelioid mesothelioma is a rare and aggressive form of cancer that affects the mesothelial cells that line the lungs, heart and abdomen. It is caused by exposure to asbestos, a mineral fiber that was once widely used in industrial and commercial products. The disease is often fatal, with a median survival rate of less than one year.
Fortunately, researchers have made significant progress in understanding this deadly form of cancer. In recent years, they have identified several gene mutations that are associated with the development of epithelioid mesothelioma. They have also developed new treatments and therapies that are aimed at slowing the progression of the disease and extending the life expectancy of those affected by it.
One of the most promising recent developments in the research of epithelioid mesothelioma is the development of targeted therapies. These therapies are designed to specifically target the genetic mutations that cause the disease. This allows the treatments to be more effective and less toxic than traditional chemotherapy.
Recently, researchers have also been developing immunotherapies that are designed to boost the patient’s own immune system to help fight the cancer. This type of treatment has been found to be successful in some cases, but more research is needed to determine its effectiveness in treating epithelioid mesothelioma.
In addition, researchers are also studying the role of non-traditional treatments such as acupuncture and herbal remedies. While these treatments have not been proven to be effective in treating epithelioid mesothelioma, they may be beneficial in providing comfort to those affected by the disease.
Overall, there has been significant progress in the research of epithelioid mesothelioma in recent years. While the disease remains incurable, researchers are hopeful that new treatments will be developed in the near future that will extend the life expectancy of those affected by it.